Peer-reviewed veterinary case report
Dog with B cell lymphoma shows cytokine release syndrome after CAR-T
By Matthew J. Atherton et al.·Published in Frontiers in Veterinary Science·2022·Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, United States, CH·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells
- Species:
- dog
Plain-English summary
A dog with relapsed B cell lymphoma was treated with a special therapy called CAR-T cells and developed symptoms like lethargy and fever three days later. Tests showed that certain immune markers were elevated, indicating a condition known as cytokine release syndrome (CRS), which can occur after this type of treatment. This case highlights the potential side effects of CAR-T therapy in dogs and suggests that further research could help improve safety and treatment options for canine cancer patients. The dog’s condition was monitored closely, and the findings could lead to better management of CRS in future cases.
People also search for: dog lymphoma treatment · CAR-T therapy side effects in dogs · why is my dog lethargic after cancer treatment
Abstract
BackgroundChimeric antigen receptor-T (CAR-T) cells have transformed the treatment of human B cell malignancies. With the advent of CAR-T therapy, specific and in some cases severe toxicities have been documented with cytokine release syndrome (CRS) being the most frequently reported. As dogs develop tumors spontaneously and in an immunocompetent setting, they provide a unique translational opportunity to further investigate the activity and toxicities associated with CAR-T therapy. Although various adoptive cellular therapy (ACT) trials have been documented and several more are ongoing in canine oncology, CRS has not been comprehensively described in canine cancer patients.Case PresentationHere we present the clinical and serologic changes in a dog treated with autologous CAR-T for relapsed B cell lymphoma that presented with lethargy and fever 3 days following CAR-T. Multiplexed serum cytokine profiling revealed increases in key cytokines implicated in human CRS including IL-6, MCP-1, IFNγ and IL-10 at or shortly after peak CAR-T levels in vivo.ConclusionThe observations noted in this case report are consistent with CRS development following CAR-T therapy in a canine patient. The dog represents a compelling model to study the pathophysiology of CRS and pre-clinically screen novel therapeutics to prevent and treat this life-threatening condition in the setting of a complex and naturally evolved immune system.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.3389/fvets.2022.824982